KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Equity Average (2016 - 2025)

Historic Equity Average for Jazz Pharmaceuticals (JAZZ) over the last 15 years, with Q3 2025 value amounting to $3.8 billion.

  • Jazz Pharmaceuticals' Equity Average fell 338.15% to $3.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 billion, marking a year-over-year decrease of 338.15%. This contributed to the annual value of $3.9 billion for FY2024, which is 1477.45% up from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' Equity Average stood at $3.8 billion, which was down 338.15% from $3.9 billion recorded in Q2 2025.
  • Jazz Pharmaceuticals' Equity Average's 5-year high stood at $4.1 billion during Q1 2025, with a 5-year trough of $2.9 billion in Q4 2022.
  • Moreover, its 5-year median value for Equity Average was $3.7 billion (2024), whereas its average is $3.7 billion.
  • Its Equity Average has fluctuated over the past 5 years, first soared by 3325.67% in 2021, then tumbled by 2631.97% in 2022.
  • Over the past 5 years, Jazz Pharmaceuticals' Equity Average (Quarter) stood at $4.0 billion in 2021, then decreased by 26.23% to $2.9 billion in 2022, then grew by 23.93% to $3.6 billion in 2023, then increased by 14.37% to $4.1 billion in 2024, then decreased by 7.25% to $3.8 billion in 2025.
  • Its Equity Average stands at $3.8 billion for Q3 2025, versus $3.9 billion for Q2 2025 and $4.1 billion for Q1 2025.